Innovent's IBI343 Yapatsidwa Udindo Wabwino wa Chithandizo cha Khansa Yapamwamba ya Pancreatic ya CLDN18.2

Pa June 19, Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) inalengeza kuti IBI343 ya Innovent Biologics yaperekedwa kuti iphatikizidwe mu pulogalamu yodziwika bwino ya chithandizo, yopangidwira kuchiza khansa ya kapamba yomwe ili ndi CLDN18.2 ndipo yalandira chithandizo chamankhwala osachepera kawiri m'mbuyomu.

IBI343 ndi mankhwala opangidwa ndi munthu omwe amapangidwanso kuti achepetse kuchuluka kwa ma antibodies a CLDN18.2 (ADC). Akamangirira ku maselo a chotupa omwe ali ndi CLDN18.2, amakumana ndi CLDN18.2-dependent ADC internalization ndipo amachotsa poizoni wambiri, zomwe zimapangitsa kuti DNA iwonongeke komanso kuti maselo a chotupa atuluke.

Pa Disembala 9, 2024, deta yaposachedwa kuchokera ku mayeso azachipatala a Phase I (NCT05458219) a IBI343 mu advanced pancreatic ductal adenocarcinoma (PDAC) idaperekedwa ku Msonkhano Wapachaka wa European Society for Medical Oncology Asia (ESMO Asia).

Odwala onse 43 omwe ali ndi CLDN18.2-positive advanced PDAC adathandizidwa ndi IBI343. Zotsatira zake zidawonetsa kuchuluka kwa mayankho olunjika (ORR) kwa 32.6%, kuchuluka kwa mayankho otsimikizika (cORR) kwa 23.3%, ndi kuchuluka kwa kulamulira matenda otsimikizika (cDCR) kwa 81.4%. Nthawi yapakati yoyankha (mDoR) inali miyezi 7.0, ndi kuchuluka kwa DoR kwa miyezi 6 kwa 63%, ndipo kupulumuka kosapitirira muyeso (PFS) kwapakati kunali miyezi 5.3.

Pakadali pano, pali mayesero ambiri azachipatala a ukadaulo watsopano wothana ndi khansa ku China omwe akufuna odwala. Mukafunsira mankhwala ndi ukadaulo watsopano, mutha kulumikizana ndi Dipatimenti Yapadziko Lonse ya Chipatala cha Oncology ku Beijing South Region.

Nambala ya Foni: 4008803716

Email：myimmnet@163.com